260 related articles for article (PubMed ID: 29077926)
21. Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens.
López-Cortés LF; Castaño MA; López-Ruz MA; Rios-Villegas MJ; Hernández-Quero J; Merino D; Jiménez-Aguilar P; Marquez-Solero M; Terrón-Pernía A; Tellez-Pérez F; Viciana P; Orihuela-Cañadas F; Palacios-Baena Z; Vinuesa-Garcia D; Fajardo-Pico JM; Romero-Palacios A; Ojeda-Burgos G; Pasquau-Liaño J
PLoS One; 2016; 11(2):e0148924. PubMed ID: 26872331
[TBL] [Abstract][Full Text] [Related]
22. An apparent paradox: resistance mutations in HIV-1 DNA predict improved virological responses to antiretroviral therapy.
Geretti AM; Abdullahi A; Mafotsing Fopoussi O; Bonnett L; Defo VF; Moudourou S; Fokam J; Kouanfack C; Torimiro J
J Antimicrob Chemother; 2019 Oct; 74(10):3011-3015. PubMed ID: 31299067
[TBL] [Abstract][Full Text] [Related]
23. Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.
Lambert-Niclot S; Flandre P; Valantin MA; Peytavin G; Sayon S; Morand-Joubert L; Delaugerre C; Algarte-Genin M; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2012 Jun; 67(6):1470-4. PubMed ID: 22396434
[TBL] [Abstract][Full Text] [Related]
24. Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy.
Vizcarra P; Blanco JL; Montejano R; Negredo E; Espinosa N; Casado JL;
Infect Dis (Lond); 2020 Mar; 52(3):202-206. PubMed ID: 31760833
[No Abstract] [Full Text] [Related]
25. HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.
Rhee SY; Jordan MR; Raizes E; Chua A; Parkin N; Kantor R; Van Zyl GU; Mukui I; Hosseinipour MC; Frenkel LM; Ndembi N; Hamers RL; Rinke de Wit TF; Wallis CL; Gupta RK; Fokam J; Zeh C; Schapiro JM; Carmona S; Katzenstein D; Tang M; Aghokeng AF; De Oliveira T; Wensing AM; Gallant JE; Wainberg MA; Richman DD; Fitzgibbon JE; Schito M; Bertagnolio S; Yang C; Shafer RW
PLoS One; 2015; 10(12):e0145772. PubMed ID: 26717411
[TBL] [Abstract][Full Text] [Related]
26. HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.
Blanch-Lombarte O; Santos JR; Peña R; Jiménez-Moyano E; Clotet B; Paredes R; Prado JG
J Antimicrob Chemother; 2020 Sep; 75(9):2535-2546. PubMed ID: 32556165
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study.
Gori A; Antinori A; Vergori A; Cossu MV; Menzaghi B; Sterrantino G; Rusconi S; Cattelan AM; Castelli F; Gianotti N; Orofino G; Ripamonti D; Savinelli S; Manzillo E; Santantonio TA; Celesia BM; Cauda R; Maserati R; d'Arminio Monforte A; Stingone C; Bonora S; Uglietti A; Termini R; Rucci F; Mancusi D
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):290-294. PubMed ID: 32101882
[TBL] [Abstract][Full Text] [Related]
28. Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens.
Armenia D; Di Carlo D; Maffongelli G; Borghi V; Alteri C; Forbici F; Bertoli A; Gori C; Giuliani M; Nicastri E; Zaccarelli M; Pinnetti C; Cicalini S; D'Offizi G; Ceccherini-Silberstein F; Mussini C; Antinori A; Andreoni M; Perno CF; Santoro MM
HIV Med; 2017 Jan; 18(1):21-32. PubMed ID: 27353061
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of darunavir/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: a multicenter clinical experience.
Gazzola L; Cicconi P; Ripamonti D; Di Filippo E; Gustinetti G; Di Biagio A; Marchetti G; Bini T; d'Arminio Monforte A
HIV Clin Trials; 2014; 15(4):140-50. PubMed ID: 25143023
[TBL] [Abstract][Full Text] [Related]
30. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.
Ofotokun I; Na LH; Landovitz RJ; Ribaudo HJ; McComsey GA; Godfrey C; Aweeka F; Cohn SE; Sagar M; Kuritzkes DR; Brown TT; Patterson KB; Para MF; Leavitt RY; Villasis-Keever A; Baugh BP; Lennox JL; Currier JS;
Clin Infect Dis; 2015 Jun; 60(12):1842-51. PubMed ID: 25767256
[TBL] [Abstract][Full Text] [Related]
32. Baseline PI susceptibility by HIV-1 Gag-protease phenotyping and subsequent virological suppression with PI-based second-line ART in Nigeria.
Datir R; El Bouzidi K; Dakum P; Ndembi N; Gupta RK
J Antimicrob Chemother; 2019 May; 74(5):1402-1407. PubMed ID: 30726945
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials.
Arribas JR; Girard PM; Paton N; Winston A; Marcelin AG; Elbirt D; Hill A; Hadacek MB
HIV Med; 2016 May; 17(5):358-67. PubMed ID: 26709605
[TBL] [Abstract][Full Text] [Related]
34. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
[TBL] [Abstract][Full Text] [Related]
35. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
Brogan A; Mauskopf J; Talbird SE; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348
[TBL] [Abstract][Full Text] [Related]
36. Analysis of virological response to therapy and resistance profile in treatment-experienced and naive HIV-1 infected Romanian patients receiving regimens containing darunavir boosted with ritonavir or cobicistat.
Marin RC; Streinu-Cercel A; Moleriu LC; Bungau SG
Biomed Pharmacother; 2022 Jun; 150():113077. PubMed ID: 35658217
[TBL] [Abstract][Full Text] [Related]
37. A detailed characterization of drug resistance during darunavir/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance.
Abdullahi A; Diaz AG; Fopoussi OM; Beloukas A; Defo VF; Kouanfack C; Torimiro J; Geretti AM
J Antimicrob Chemother; 2024 Feb; 79(2):339-348. PubMed ID: 38153241
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
Madeddu G; Rusconi S; Cozzi-Lepri A; Di Giambenedetto S; Bonora S; Carbone A; De Luca A; Gianotti N; Di Biagio A; Antinori A;
Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212
[TBL] [Abstract][Full Text] [Related]
39. Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.
Charpentier C; Lee GQ; Rodriguez C; Visseaux B; Storto A; Fagard C; Molina JM; Katlama C; Yazdanpanah Y; Harrigan PR; Descamps D
J Antimicrob Chemother; 2015 Jul; 70(7):2090-6. PubMed ID: 25755001
[TBL] [Abstract][Full Text] [Related]
40. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
